Holen Sie sich die Stockscreener-App
0.9099
1.50%
-0.0138
Handel nachbörslich:
.91
0.000100
+0.01%
Schlusskurs vom Vortag:
$0.9237
Offen:
$0.9249
24-Stunden-Volumen:
124.48K
Relative Volume:
0.38
Marktkapitalisierung:
$27.02M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-10.21M
KGV:
-1.5575
EPS:
-0.5842
Netto-Cashflow:
-
1W Leistung:
-10.79%
1M Leistung:
+13.74%
6M Leistung:
-55.18%
1J Leistung:
-13.34%
1-Tages-Spanne:
$0.8701
$0.9358
1-Wochen-Bereich:
$0.8701
$1.08
52-Wochen-Spanne:
$0.6801
$2.60
Neurosense Therapeutics Ltd Stock (NRSN) Company Profile
Firmenname
Neurosense Therapeutics Ltd
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie NRSN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NRSN
Neurosense Therapeutics Ltd
|
0.9099 | 27.43M | 0 | -10.21M | 0 | -0.5842 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Neurosense Therapeutics Ltd Aktie (NRSN) Neueste Nachrichten
Short Covering: Can SNVPRE expand into new marketsOil Prices & Verified Momentum Stock Watchlist - baoquankhu1.vn
Breakouts Watch: Is NeuroSense Therapeutics Ltd Equity Warrant showing insider buying2025 Winners & Losers & Reliable Momentum Entry Alerts - baoquankhu1.vn
Valuation Update: What is DMACs revenue forecastEarnings Overview Report & AI Based Buy/Sell Signal Reports - baoquankhu1.vn
Analysis Recap: Can NeuroSense Therapeutics Ltd Equity Warrant keep up with sector leadersLayoff News & Fast Entry Momentum Alerts - baoquankhu1.vn
NeuroSense’s ALS drug PrimeC shows success in phase 2b, eyes final trial - MSN
New Alzheimer’s treatment from NeuroSense gets U.S. patent through 2043 - Stock Titan
Analyst Calls: Is NeuroSense Therapeutics Ltd gaining market sharePortfolio Value Report & Proven Capital Preservation Methods - baoquankhu1.vn
Is NeuroSense Therapeutics Ltd. a momentum stockFed Meeting & Long Hold Capital Preservation Tips - bollywoodhelpline.com
Portfolio Shifts: Is NeuroSense Therapeutics Ltd Equity Warrant showing insider buyingJuly 2025 Update & Long-Term Capital Growth Ideas - baoquankhu1.vn
Big Picture: What are NeuroSense Therapeutics Ltd Equity Warrants recent SEC filings showingQuarterly Investment Review & Free High Return Stock Watch Alerts - baoquankhu1.vn
Weekly Trades: Is NeuroSense Therapeutics Ltd Equity Warrant benefiting from interest rate changes2025 Volatility Report & Growth Focused Stock Reports - baoquankhu1.vn
Ideas Watch: Will NeuroSense Therapeutics Ltd face regulatory challengesWeekly Trend Report & Technical Pattern Based Signals - baoquankhu1.vn
Weekly Trades: Why is NeuroSense Therapeutics Ltd stock going downInsider Selling & Daily Profit Focused Screening - baoquankhu1.vn
Aug Highlights: Is SNOA likely to announce a buybackIPO Watch & Fast Entry High Yield Tips - baoquankhu1.vn
Earnings Recap: Will NeuroSense Therapeutics Ltd Equity Warrant stock go up in YEARJuly 2025 Outlook & Technical Entry and Exit Tips - baoquankhu1.vn
RSI Check: Why NeuroSense Therapeutics Ltd stock appeals to analysts2025 Breakouts & Breakdowns & Daily Profit Focused Stock Screening - Bộ Nội Vụ
Bear Alert: Can NeuroSense Therapeutics Ltd stock beat analyst upgradesJuly 2025 Price Swings & Weekly High Momentum Picks - Bộ Nội Vụ
Risk Hedge: Is NeuroSense Therapeutics Ltd stock a good choice for value investorsJuly 2025 PostEarnings & Verified Swing Trading Watchlists - Bộ Nội Vụ
How NeuroSense Therapeutics Ltd. stock benefits from tech adoptionEarnings Recap Summary & Verified Entry Point Signals - ulpravda.ru
Why NeuroSense Therapeutics Ltd. Equity Warrant stock appeals to analystsProfit Target & Weekly High Return Stock Forecasts - Улправда
Will NeuroSense Therapeutics Ltd. stock remain a Wall Street favorite2025 Volume Leaders & Stepwise Entry and Exit Trade Signals - Улправда
Technical Analysis: What risks investors should watch in NeuroSense Therapeutics Ltd stockRate Cut & Verified Stock Trade Ideas - Bộ Nội Vụ
World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB - Sahm
What risks investors should watch in NeuroSense Therapeutics Ltd. stockForecast Cut & Precise Swing Trade Entry Alerts - ulpravda.ru
Is NeuroSense Therapeutics Ltd. stock resilient to inflationGlobal Markets & Weekly High Momentum Picks - Улправда
Will NeuroSense Therapeutics Ltd. Equity Warrant stock recover faster than peersJuly 2025 WrapUp & Weekly Market Pulse Updates - Улправда
NeuroSense Therapeutics Ltd.Ordinary Shares (NQ: NRSN - FinancialContent
How NeuroSense Therapeutics Ltd. Equity Warrant stock responds to policy changesWeekly Risk Summary & Weekly High Potential Alerts - Улправда
Can NeuroSense Therapeutics Ltd. stock resist sector downturnsWeekly Investment Recap & High Return Stock Watch Alerts - Улправда
Trading Recap: Will NeuroSense Therapeutics Ltd. (H1Z) stock justify high valuation2025 Price Momentum & Fast Gain Stock Tips - Улправда
Can NeuroSense Therapeutics Ltd. stock continue upward trendBreakout Watch & Free AI Powered Buy and Sell Recommendations - Улправда
Is NeuroSense Therapeutics Ltd. Equity Warrant stock a good choice for value investors2025 Support & Resistance & Precise Swing Trade Alerts - Улправда
NeuroSense Therapeutics Ltd. Appoints Prof. Steven E. Arnold to Scientific Advisory Board - MarketScreener
Hedge Fund Bets: How NeuroSense Therapeutics Ltd. Equity Warrant stock performs after earningsJuly 2025 Intraday Action & Weekly Setup with ROI Potential - Улправда
Harvard Alzheimer’s doctor joins biotech developing neurodegenerative treatments - Stock Titan
NeuroSense Shareholders Approve Equity Grants to Directors and CEO to Preserve Cash - TipRanks
How NeuroSense Therapeutics Ltd. stock compares to growth peers2026 world cup usa national team semifinals defensive leaders set piece tactics match prediction analysis - ulpravda.ru
NeuroSense Therapeutics (NASDAQ:NRSN) Upgraded by Wall Street Zen to Hold Rating - Defense World
NeuroSense Therapeutics Ltd. (NASDAQ:NRSNW) Short Interest Down 15.5% in December - Defense World
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Weekly Buzz: FDA OKs Roche's Lunsumio VELO; It's No For Tolbrutinib; BioMarin, SNY Open Wallets - RTTNews
NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study - Sahm
NeuroSense Unveils Favourable Safety Analysis Data Of PrimeC In NST-AD-001 Study For Alzheimer's - Nasdaq
NeuroSense Therapeutics (NASDAQ:NRSN) Receives Buy Rating from D. Boral Capital - Defense World
D. Boral Capital Maintains NeuroSense Therapeutics (NRSN) Buy Recommendation - Nasdaq
NeuroSense Reports Favorable Safety Profile for PrimeC in Phase 2 Alzheimer’s Trial - TipRanks
Neurosense stock rises as Alzheimer’s drug shows favorable safety profile By Investing.com - Investing.com South Africa
Neurosense stock rises as Alzheimer’s drug shows favorable safety profile - Investing.com
Experimental Alzheimer's combo shows no serious side effects in trial - Stock Titan
Rally Mode: Is Capella Minerals Limited (N7D) stock worth buying before Fed actionEarnings Overview Summary & Safe Capital Investment Plans - moha.gov.vn
Will NeuroSense Therapeutics Ltd. stock pay special dividends2025 Volume Leaders & Verified Swing Trading Watchlists - Улправда
Finanzdaten der Neurosense Therapeutics Ltd-Aktie (NRSN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.09%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):